Search

Introduction: The aim of the vigilance system in Switzerland is the evaluation and classification of reported suspected adverse reactions of immunological veterinary medicines (IVMP), including suspected lack of expected efficacy. The Institute of Virology and Immunology (IVI) is the competent authority for marketing authorizations of immunological veterinary medicinal products in Switzerland and responsible for the vaccinovigilance system. In 2020, 130 adverse reaction reports were received (5% less compared to 2019). The reports mainly concerned dogs (41%) and cats (25%) followed by cattle (18%) and horses (7%). Many of the reports in dogs involved the application of combined vaccines against canine distemper, hepatitis, parvovirosis and parainfluenza in combination with canine leptospira components, in cats against cat flu and feline panleukopenia in combination with feline leukaemia virus infection. Causality assessments were done according to the international ABON system. In 27% of the reported cases, the causality assessments between the vaccination and the reaction described were evaluated as being probable (ABON A), in 44% as possible (ABON B).

Introduction: The registration of adverse events after the use of immunological veterinary medicinal products (IVMP) is the aim of the vigilance reporting system in Switzerland. Adverse events comprise suspected adverse reactions and lack of expected efficacy. Since the Institute of virology and immunology (IVI) is the competent authority for the regulation of immunological VMP in Switzerland, the reporting system is administrated by the IVI. In 2019, 137 reports concerning authorized immunological VMP were received (15% less compared to 2018). While most of the reports were submitted by the marketing authorization holders (56%), practicing veterinary surgeons contributed to the reporting system, too (40%). This corresponds to an increase of 22% of reported adverse events by the practicing veterinary surgeons compared to the previous year. Private persons (4%) submitted five reports. In comparison to 2018, in 2019 79% of the adverse events were reported by marketing authorization holders and 18% by veterinarians. Dogs (55%) and cats (20%) were mainly affected. Further reports were related to cattle (13%) and horses (5%). Recently, the numbers of reports concerning dogs (+12%) and cats (+4%) have considerably increased. Most of the reports were based on the application of vaccines against canine distemper, hepatitis, parvovirosis and parainfluenza in combination with leptospirosis in dogs as well as cat flu and feline panleukopenia in cats. In 34% of the submitted cases, the causality assessment between the vaccination and the reaction described was evaluated as probable.